SCHEMBL2383147

SCHEMBL2383147

CCc1cccc(NC(=O)N2CCN(c3nsnc3OCc3ccncc3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
P2RY12 Q9H244 5/20 0.45
PDGFRB P09619 4/20 0.44
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
FAAH O00519 1/20 0.43
PDGFRA P16234 1/20 0.42
KDR P35968 1/20 0.42
KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385749 0.90 P2RY12 (0.47) P2RY12PDGFRBDRD2DRD4DRD3
SCHEMBL2385186 0.90 MEN1 (0.43) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL5573660 0.89 MEN1 (0.44) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL2385551 0.88 TRPV1 (0.51) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL2385110 0.88 MAPT (0.52) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL12250952 0.88 P2RY12 (0.41) MEN1KMT2AP2RY12PDGFRBDRD2
SCHEMBL2385630 0.86 ALDH1A1 (0.49) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL2384352 0.86 MEN1 (0.42) MEN1KMT2AP2RY12PDGFRBALDH1A1
SCHEMBL2384560 0.86 TRPV1 (0.53) MEN1KMT2AMAPK1HSD17B10FAAH
SCHEMBL2384924 0.85 PI4KB (0.44) MEN1KMT2AP2RY12PDGFRBDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR MEN1 1132/4885KMT2A 682/4885P2RY12 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.